Switch theme
Sign up to access all valuation multiples
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
2007
395
LTM Revenue $346M
LTM EBITDA -$11.3M
$993M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ardelyx has a last 12-month revenue of $346M and a last 12-month EBITDA of -$11.3M.
In the most recent fiscal year, Ardelyx achieved revenue of $334M and an EBITDA of -$16.7M.
Ardelyx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ardelyx valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $124M | $334M | XXX | XXX | XXX |
| Gross Profit | $48.0M | $107M | XXX | XXX | XXX |
| Gross Margin | 39% | 32% | XXX | XXX | XXX |
| EBITDA | -$55.4M | -$16.7M | XXX | XXX | XXX |
| EBITDA Margin | -44% | -5% | XXX | XXX | XXX |
| Net Profit | -$67.2M | -$66.1M | XXX | XXX | XXX |
| Net Margin | -54% | -20% | XXX | XXX | XXX |
| Net Debt | n/a | $28.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ardelyx's stock price is $5.
Ardelyx has current market cap of $1.1B, and EV of $993M.
See Ardelyx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $993M | $1.1B | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ardelyx has market cap of $1.1B and EV of $993M.
Ardelyx's trades at 2.9x LTM EV/Revenue multiple, and -87.6x LTM EBITDA.
Analysts estimate Ardelyx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ardelyx and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $993M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | -59.4x | XXX | XXX | XXX |
| P/E | -27.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -21.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpArdelyx's NTM/LTM revenue growth is 20%
Ardelyx's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.8M for the same period.
Over next 12 months, Ardelyx's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ardelyx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ardelyx and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 168% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -5% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -70% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 15% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.8M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 93% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ardelyx acquired XXX companies to date.
Last acquisition by Ardelyx was XXXXXXXX, XXXXX XXXXX XXXXXX . Ardelyx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ardelyx founded? | Ardelyx was founded in 2007. |
| Where is Ardelyx headquartered? | Ardelyx is headquartered in United States of America. |
| How many employees does Ardelyx have? | As of today, Ardelyx has 395 employees. |
| Who is the CEO of Ardelyx? | Ardelyx's CEO is Mr. Michael G. Raab. |
| Is Ardelyx publicy listed? | Yes, Ardelyx is a public company listed on NAS. |
| What is the stock symbol of Ardelyx? | Ardelyx trades under ARDX ticker. |
| When did Ardelyx go public? | Ardelyx went public in 2014. |
| Who are competitors of Ardelyx? | Similar companies to Ardelyx include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ardelyx? | Ardelyx's current market cap is $1.1B |
| What is the current revenue of Ardelyx? | Ardelyx's last 12-month revenue is $346M. |
| What is the current EBITDA of Ardelyx? | Ardelyx's last 12-month EBITDA is -$11.3M. |
| What is the current EV/Revenue multiple of Ardelyx? | Current revenue multiple of Ardelyx is 2.9x. |
| What is the current EV/EBITDA multiple of Ardelyx? | Current EBITDA multiple of Ardelyx is -87.6x. |
| What is the current revenue growth of Ardelyx? | Ardelyx revenue growth between 2023 and 2024 was 168%. |
| Is Ardelyx profitable? | Yes, Ardelyx is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
